Robert Vescio

10.4k total citations
150 papers, 6.0k citations indexed

About

Robert Vescio is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Robert Vescio has authored 150 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Hematology, 73 papers in Molecular Biology and 72 papers in Oncology. Recurrent topics in Robert Vescio's work include Multiple Myeloma Research and Treatments (105 papers), Protein Degradation and Inhibitors (41 papers) and Cancer Treatment and Pharmacology (23 papers). Robert Vescio is often cited by papers focused on Multiple Myeloma Research and Treatments (105 papers), Protein Degradation and Inhibitors (41 papers) and Cancer Treatment and Pharmacology (23 papers). Robert Vescio collaborates with scholars based in United States, Germany and Canada. Robert Vescio's co-authors include James R. Berenson, Alan Lichtenstein, Regina A. Swift, Yiping Tu, Gary J. Schiller, Hank H. Yang, Matthew B. Rettig, Daniel C. Douek, Brenna J. Hill and Michael R. Betts and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Robert Vescio

144 papers receiving 5.8k citations

Peers

Countries citing papers authored by Robert Vescio

Since Specialization

Citations

This map shows the geographic impact of Robert Vescio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Vescio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Vescio more than expected).

Fields of papers citing papers by Robert Vescio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Vescio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Vescio. The network helps show where Robert Vescio may publish in the future.

Co-authorship network of co-authors of Robert Vescio

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Vescio. A scholar is included among the top collaborators of Robert Vescio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Vescio. Robert Vescio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Daratumumab for Treatment of Recurrent FSGS and PGNMID in Kidney Transplant 2025 ·American Journal of Transplantation ·Jun Shoji, Ashley Vo, (unknown), Edmund Huang, Raymond P. Najjar, Sindhu Chandran, Dechu Puliyanda, Robert Vescio, (unknown), Stanley C. Jordan	0
2	Daratumumab (Anti-CD38) Desensitization in HLA Sensitized Patients: Long-Term Follow-Up 2025 ·American Journal of Transplantation ·Ashley Vo, Edmund Huang, Xiaohai Zhang, Robert Vescio, (unknown), (unknown), (unknown), Noriko Ammerman, (unknown), (unknown), Jun Shoji, Siddharthan Chandran, (unknown), (unknown), Matthew J. Gillespie, David L. Thomas, Borami Shin, Stanley C. Jordan	0
3	A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone 2023 ·Blood ·James R. Berenson, (unknown), Stephanie R. Rice, (unknown), Ralph V. Boccia, (unknown), Mehdi M. Moezi, Stephen Lim, Gary K. Schwartz, Shahrooz Eshaghian, Matthew Brobeck, Regina A. Swift, (unknown), Sean Bujarski, (unknown), (unknown), (unknown), Robert Vescio	1
4	Reverse Autologous Peripheral Blood Stem Cell Transplantation after Allogeneic Transplantation to Restore Immune Function and Pancytopenia 2023 ·Blood ·Robert Vescio, Yuliya Linhares, (unknown), (unknown), Amanda Park, (unknown), Amrita Krishnan	1
5	Salvage Autologous Peripheral Blood Stem Cell Transplantation after the Development of tMDS or AML in Multiple Myeloma Patients 2023 ·Blood ·Robert Vescio, (unknown), (unknown), Amanda Park, (unknown), Ronald Paquette	0
6	A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma 2020 ·Clinical Cancer Research ·James R. Berenson, (unknown), Tanya M. Spektor, (unknown), (unknown), (unknown), (unknown), (unknown), Regina A. Swift, Gary K. Schwartz, Shahrooz Eshaghian, Laura Stampleman, Robert A. Moss, Stephen Lim, Robert Vescio	25
7	Mechanical circulatory support for cardiac amyloidosis 2019 ·Clinical Transplantation ·M. Kittleson, Robert Cole, J. Patel, Danny Ramzy, Elizabeth Passano, D. Chang, (unknown), L. Czer, Robert Vescio, Joshua Chung, Jon Kobashigawa, Francisco A. Arabía, F. Esmailian, J. Moriguchi	23
8	Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy 2014 ·Leukemia ·James R. Berenson, James Hilger, Ori Yellin, Robert Dichmann, Dipti Patel‐Donnelly, Ralph V. Boccia, Alberto Bessudo, Laura Stampleman, Donald Gravenor, Shahrooz Eshaghian, Youram Nassir, Regina A. Swift, Robert Vescio	55
9	A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma 2013 ·Annals of Hematology ·James R. Berenson, James Hilger, Ori Yellin, Ralph V. Boccia, Jeffrey Matous, (unknown), Hassan Ghazal, (unknown), Edwin Kingsley, Wael A. Harb, Stephen J. Noga, Youram Nassir, Regina A. Swift, Robert Vescio	34
10	A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients 2011 ·British Journal of Haematology ·James R. Berenson, Ori Yellin, (unknown), Ravi Patel, Alberto Bessudo, Ralph V. Boccia, Hank H. Yang, Robert Vescio, Elizabeth Yung, Russell Mapes, (unknown), James Hilger, (unknown), (unknown), Youram Nassir, Regina A. Swift	25
11	Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma 2009 ·British Journal of Haematology ·Christine Chen, Donna Reece, David S. Siegel, Rubén Niesvizky, Ralph V. Boccia, Edward A. Stadtmauer, Rafat Abonour, Paul G. Richardson, Jeffrey Matous, Shaji Kumar, Nizar J. Bahlis, Melissa Alsina, Robert Vescio, Steven Coutré, Dennis Pietronigro, Robert Knight, Jerome B. Zeldis, S. Vincent Rajkumar	62
12	Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma 2009 ·British Journal of Haematology ·Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf, Elber S. Camacho, David Irwin, Jose Lutzky, Marti McKinley, (unknown), Afshin Eli Gabayan, Amitabha Mazumder, John Crowley, Robert Vescio	37
13	Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases 2002 ·The Journal of Clinical Pharmacology ·Tianling Chen, James R. Berenson, Robert Vescio, Regina A. Swift, (unknown), Susan Goodin, Patricia LoRusso, Peiming Ma, Christina Ravera, (unknown), Horst Schran, John J. Seaman, Andrej Skerjanec	310
14	Malignant Multiple Myeloma (MM) Cells Express RANKL, A Moderator of Osteoclast Activation 2001 ·Journal of Bone and Mineral Metabolism ·(unknown), (unknown), (unknown), (unknown), (unknown), Robert Vescio, (unknown)	1
15	A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease 2001 ·Cancer ·James R. Berenson, Robert Vescio, (unknown), Carol Y. Nishikubo, Matthew B. Rettig, Regina A. Swift, Francisco Conde, (unknown)	66
16	Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution 2000 ·The Lancet ·Daniel C. Douek, Robert Vescio, Michael R. Betts, Jason M. Brenchley, Brenna J. Hill, Lan Zhang, James R. Berenson, Robert H. Collins, Richard A. Koup	453
17	THE ROLE OF HUMAN HERPESVIRUS-8 IN THE PATHOGENESIS OF MULTIPLE MYELOMA 1999 ·Hematology/Oncology Clinics of North America ·Nelida Sjak-Shie, Robert Vescio, James R. Berenson	11
18	Identification of a New, Unorthodox Member of the MAGE Gene Family 1999 ·Genomics ·Mehis Pǒld, Jin Zhou, (unknown), Jeffrey M. Hall, Robert Vescio, (unknown)	68
19	Interleukin-6 Inhibits Apoptosis of Malignant Plasma Cells 1995 ·Cellular Immunology ·Alan Lichtenstein, Yiping Tu, Catherine Fady, Robert Vescio, James R. Berenson	244
20	BCL-X expression in multiple myeloma: possible indicator of chemoresistance. 1990 ·Dialnet (Universidad de la Rioja) ·Yiping Tu, (unknown), Fei Xu, A. Fleishman, Jeremy M. G. Taylor, Judith Weisz, Robert Vescio, Matthew B. Rettig, James Berenson, Stanisław Krajewski, John C. Reed, Alan Lichtenstein	201

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact